Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260607 · ClinicalTrials.gov registry record · Phase 3
Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department
A Phase 3 study, sponsored by Naval Medical Center Camp Lejeune.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT04260607 is a Phase 3 study that was terminated before completion, run by Naval Medical Center Camp Lejeune. The registered enrollment target is 1 participants.
The verdict
NCT04260607, a Phase 3 study, was terminated before completion, sponsored by Naval Medical Center Camp Lejeune.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
Current treatment for acutely suicidal patients are limited to hospitalization, psychotherapy, electro-convulsant therapy, or a combination of the aforementioned. However, this has added to the national boarding problem. Long term pharmacologic treatment for suicidal behaviors and mood stabilization has been studied in specific populations. In these populations, the decreases in suicidal ideation results from stabilization of the underlying psychiatric illness. Ketamine is most commonly used as an anesthetic with analgesic properties. It has been used off-label for pain management, procedural sedation, status epilepticus, and treatment resistant depression. It has been safely administered intravenously and well tolerated for chronic Post Traumatic Stress Disorder. It increases norepinephrine, dopamine, and serotonin through adrenergic neuron stimulation and prevention of catecholamine uptake. There is a strong corollary between stress and the development of depression and suicidal behaviors. It is proposed that the use of low dose intravenous ketamine may have benefit on the suicidal ideation of patients presenting to the Emergency Department.
Interventions
- DRUG Normal saline
- DRUG Ketamine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04260607
The ClinicalTrials.gov registry entry for NCT04260607 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naval Medical Center Camp Lejeune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT04260607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04260607 about?
NCT04260607 is a clinical study titled "Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department". Current treatment for acutely suicidal patients are limited to hospitalization, psychotherapy, electro-convulsant therapy, or a combination of the aforementioned. However, this has added to the national boarding problem. Long term pharmacologic treatment for suicidal behaviors and mood stabilization...
What is the current status of trial NCT04260607?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2020-01-14. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT04260607?
The interventions under investigation include: Normal saline (DRUG), Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04260607?
This trial is sponsored by Naval Medical Center Camp Lejeune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.